For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
5
views
9
references
 Top references
cited by
111
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      2,464
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          While vitamin E has shown to improve nonalcoholic steatohepatitis (NASH) in patients without diabetes, information on patients with type 2 diabetes mellitus (T2DM) is lacking. The aim of this study was to determine whether vitamin E, alone or combined with pioglitazone, improves histology in patients with T2DM and NASH.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Endpoints and clinical trial design for nonalcoholic steatohepatitis.

          Arun Sanyal, Elizabeth Brunt, David Kleiner … (2011)
          Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease. At present, a liver biopsy is the only generally acceptable method for the diagnosis of NASH and assessment of its progression toward cirrhosis. Although several treatments have shown evidence of efficacy in clinical trials of varying design, there are no approved treatments for NASH, and published trials are often too divergent to allow meaningful comparisons. There is thus a lack of established noninvasive, point-of-care diagnostics and approved treatment on one hand and a substantial population burden of disease on the other. These provide the rationale for developing consensus on key endpoints and clinical trial design for NASH. This article summarizes the consensus arrived at a meeting of the American Association for the Study of Liver Diseases on the key endpoints and specific trial design issues that are germane for development of diagnostic biomarkers and treatment trials for NASH. Copyright © 2011 American Association for the Study of Liver Diseases.
          Article 0 comments Cited 227 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

            (2016)
            Article 0 comments Cited 215 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.

              Giovanni Musso, Maurizio Cassader, Elena Paschetta … (2017)
              Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplantation by 2020. Advanced fibrosis (stage F3-F4) on liver biopsy independently predicts all-cause and liver-related mortality in NASH. There are no known efficacious treatments for advanced fibrosis related to NASH. Thiazolidinedione therapy has been extensively evaluated in NASH, and new randomized clinical trials (RCTs) of its efficacy have been completed.
              Article 0 comments Cited 173 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Title: Diabetes Care
                Abbreviated Title: Dia Care
                Publisher: American Diabetes Association
                ISSN (Print): 0149-5992
                ISSN (Electronic): 1935-5548
                Publication date Created: July 22 2019
                Publication date Created: August 2019
                Publication date (Print): August 2019
                Publication date (Electronic): May 21 2019
                Volume: 42
                Issue: 8
                Pages: 1481-1488
                Article
                DOI: 10.2337/dc19-0167
                PubMed ID: 31332029
                SO-VID: 8bdba444-b37a-477f-b90d-1e12e7df6e25
                Copyright © © 2019
                License:

                Free to read

                http://www.diabetesjournals.org/site/license

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content2,464

                See all similar

                Cited by110

                See all cited by

                Most referenced authors671

                See all reference authors